Agilent Technologies Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Agilent Technologies Inc trades at $148.72 (market cap $42.22B), while State Street SPDR S&P Homebuilders ETF trades at $110.22. The key difference: Agilent Technologies Inc pays a 0.68% dividend while State Street SPDR S&P Homebuilders ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| A | XHB | |
|---|---|---|
Market Cap | $42.22B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $157.20 | $121.36 |
52-Week Low | $110.24 | $94.86 |
Enterprise Value | $43.77B | — |
Dividend Yield | 0.68% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XHB (SPDR S&P Homebuilders ETF) trades at $110.80, up 1.83% with bullish technical signals from moving averages. The ETF benefits from positive housing market developments including new home sales growth and landmark housing legislation. Technical indicators show strong momentum with the current price above key support levels, though RSI suggests potential overbought conditions in the short term.
The outlook remains constructive given supportive housing policy and improving builder sentiment, though risks include mortgage rate sensitivity and inventory constraints. With institutional analysis highlighting XHB's exposure to housing recovery themes, the ETF offers targeted homebuilding sector exposure amid a mixed but stabilizing residential market environment.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →